Receptos Completes Enrollment of RADIANCE Phase 3 Trial of Ozanimod in Relapsing Multiple Sclerosis

By: via Benzinga
Receptos, Inc. (Nasdaq: RCPT) announced today that the Company has completed enrollment in the RADIANCE Phase 3 trial of ozanimod ...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.